Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

4 terminated/withdrawn out of 32 trials

Success Rate

78.9%

-7.6% vs industry average

Late-Stage Pipeline

3 trials in Phase 3/4

Results Transparency

0 of 15 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

N/A

11(64.7%)

Phase 3

3(17.6%)

Phase 2

2(11.8%)

Phase 1

1(5.9%)

17Total

N/A(11)

Phase 3(3)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (32)

Showing 20 of 32 trials

NCT04801472Not ApplicableTerminated

Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)

Role: lead

NCT05399693Completed

Platelet Transfusion Refractoriness

Role: lead

NCT06536556Terminated

Effects of a Single Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: Comparison of Paclitaxel vs Paclitaxel + Trastuzumab vs Paclitaxel + Carboplatine: the PROTECT-06 Bis Study

Role: lead

NCT05803889Terminated

Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer

Role: lead

NCT04566029Completed

Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial Carcinomas

Role: collaborator

NCT06476704Phase 2Not Yet Recruiting

Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas

Role: lead

NCT06775119Not ApplicableCompleted

Feasibility Study of a Neuromuscular Fatigue Test and Associated Hemodynamic Responses: Application in Healthy Volunteers for Use in Patients with Chemotherapy-treated Breast Cancer

Role: lead

NCT06477939Phase 3Not Yet Recruiting

Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients

Role: lead

NCT06458517Not ApplicableNot Yet Recruiting

Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers

Role: lead

NCT06326268Not ApplicableRecruiting

Interest of Light Therapy in Hematology - The PHOTO-TREAT Study

Role: lead

NCT05786105Completed

Optical Genome Mapping in Characterization of Multiple Myeloma

Role: lead

NCT06149312Not ApplicableRecruiting

Feasibility of an Advance Care Planning Intervention

Role: lead

NCT04626466Completed

Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation

Role: lead

NCT04783363Not ApplicableCompleted

Study Comparing Satisfaction of Hospitalized Patients Receiving Invasive Care for Cancer Treatment, With Snoezelen Session Versus Standard Care

Role: lead

NCT05328024Recruiting

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma

Role: lead

NCT05772481Unknown

Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Role: lead

NCT05907551Unknown

Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions

Role: lead

NCT05128617Completed

Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study

Role: lead

NCT04391946Completed

Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19

Role: collaborator

NCT05355857Not ApplicableCompleted

Creation of a Probabilistic Atlas of Normal Cerebral Uptake of 18F-FDG in PET/MRI.

Role: lead